ANDY JACKSON/Stuff
Graham Walker, who has multiple sclerosis, is set to arrive in Bluff on Saturday for the Bangers to Bluff rally to raise money for Multiple Sclerosis New Zealand.
Former competitive cyclist Graham Walker is taking part in annual Bangers to Bluff charity event to help raise awareness for a revolutionary drug. The event is organised by Rotary Club of Half Moon Bay, in Auckland, and involves up to 20 cars, bought for less than $2000, to be driven to from Auckland to Bluff. The organisation donates the proceeds of the event to different charities, but the majority has been given to Hope Works and Multiple Sclerosis New Zealand in the past four years.
(0)
DGAP-News: Immunic, Inc. / Key word(s): Study results
Immunic, Inc. Announces EMPhASIS Interim Analysis of 10 mg Cohort Confirms IMU-838 s Dose Response in Relapsing-Remitting Multiple Sclerosis and Supports Phase 3 Dose Selection
15.04.2021 / 12:30
The issuer is solely responsible for the content of this announcement.
Immunic, Inc. Announces EMPhASIS Interim Analysis of 10 mg Cohort Confirms IMU-838 s Dose Response in Relapsing-Remitting Multiple Sclerosis and Supports Phase 3 Dose Selection
- Preplanned Interim Analysis of 12-Week MRI Data from 10 mg IMU-838 Dose and Placebo, in Combination with Existing 30 and 45 mg Dose Data, Establishes Clear Dose-Response Relationship for IMU-838 -
- Totality of Data Clearly Supports Decision that 30 mg Once Daily Dose of IMU-838 Will Now Be Targeted for Phase 3 Development in Relapsing-Remitting Multiple Sclerosis -
DGAP-News: Immunic, Inc. to Participate in Scientific, Investor and Industry Conferences in April
vom 13.04.2021, 12:30 Uhr
Bild: pixabay.com
Immunic, Inc. to Participate in Scientific, Investor and Industry Conferences in April
13.04.2021 / 12:30
Immunic, Inc. to Participate in Scientific, Investor and Industry Conferences in April
NEW YORK, April 13, 2021 - Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced participation in the following scientific, investor and industry conferences in April:
- April 17-22:
2021 Virtual American Academy of Neurology (AAN) Annual Meeting. Robert J. Fox, M.D., Staff Neurologist, Mellen Center for Multiple Sclerosis, Vice-Chair for Research, Neurologic Institute, Cleveland Clinic, Cleveland, Ohio, will present the full data set from Immunic s phase 2 EMPhASIS trial of its lead
DGAP-News: Immunic, Inc. to Participate in Scientific, Investor and Industry Conferences in April
Immunic, Inc. to Participate in Scientific, Investor and Industry Conferences in April
13.04.2021 / 12:30
Immunic, Inc. to Participate in Scientific, Investor and Industry Conferences in April
NEW YORK, April 13, 2021 - Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced participation in the following scientific, investor and industry conferences in April:
- April 17-22:
2021 Virtual American Academy of Neurology (AAN) Annual Meeting. Robert J. Fox, M.D., Staff Neurologist, Mellen Center for Multiple Sclerosis, Vice-Chair for Research, Neurologic Institute, Cleveland Clinic, Cleveland, Ohio, will present the full data set from Immunic s phase 2 EMPhASIS trial of its lead asset, IMU-838, in patients with relapsing-remitt
/PRNewswire/ Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at.